The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...

Vertex Pharmaceuticals Incorporated VRTX stock has plunged 25.3% this year so far against the industry’s 5.4% increase. VRTX ...

Both stocks should deliver excellent returns to investors patient enough to hold through volatility. Equity markets started ...

Vertex’s strong execution continued in the fourth quarter, wrapping up what was a very consistent year for the company. More importantly, I’m excited about our growing pipeline, which is ...

Learn more about whether Elastic N.V. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on wallstreetbets Subreddit Page by MADD-Scientis. In this ...

While Vertex’s main focus is on the development and strengthening of its CF franchise, the company also has a rapidly advancing mid- to late-stage pipeline in other disease areas beyond CF ...